Posts in Clinical Trials
What's New in Stroke?
What's New in Stroke?

Stroke is the fifth leading cause of death in the U.S. Read on to learn more about some phase 3 trials that are studying potential stroke treatment drug breakthroughs in 2022.

Read More
Blood clots, Blood thinners, Clinical Trials, Coronary Artery Disease, Drug Manufacturers, Health, Heart Disease, Medications, Prevention, Research Studies, Treatment, StrokeRoss PhanARCADIA, stroke, aspirin, heart, heart disease, Eliquis, apixaban, experimental, CAPTIVA, Plavix, clopidogrel, vascular death, blood clots, prevent blood clots, Xarelto, rivaroxaban, Brilinta, ticagrelor, FASTEST, NovoSeven, recombinant activated factor VII, rFVIIa, intracerebral hemorrhage, ICH, Bristol-Myers Squibb, Pfizer, Roche, Novo Nordisk, Columbia University, Dr. Joseph Broderick, National Institute of Health, NIH, University of Florida, AstraZeneca, Janssen, Ross Phan, abnormal heart rhythm, stent, heart attacks, bleeding conditions, bleeding problemsComment
FDA Approves Verzenio (Abemaciclib) for Early Breast Cancer
FDA Approves Verzenio (Abemaciclib) for Early Breast Cancer

Verzenio was already approved to treat advanced breast cancer. Now, the FDA just gave Verzenio an additional approval to treat early breast cancer. Read on to learn more about how Verzenio works and what side effects to expect.

Read More
Clinical Trials, FDA, Health, Medications, Research Studies, Women's Health, Cancer, Breast CancerRoss PhanVerzenio, Abemaciclib, HR+/HER2- breast cancer, hormone positive breast cancer, HER2 negative breast cancer, early breast cancer, CDK inhibitor, advanced breast cancer, side effects, expensive medications, limited distribution drug, LDD, specialty pharmacy, lower risk of cancer coming back, targeted therapy, Ross PhanComment
What Is an Orphan Drug? Learn How and When a Medication is Given This Designation
What Is an Orphan Drug? Learn How and When a Medication is Given This Designation

Are you curious how medications for rare diseases are developed? If so, read on to learn more about these “orphan drugs” for rare medical conditions.

Read More
Medications, Health, Rare Diseases, Drug Development, Drug Manufacturers, FDA, Clinical Trials, Research StudiesRoss Phanorphan drugs, Orphan Drug Act, post-market approval, post-market studies, expensive medications, manufacturer benefits, manufacturer incentives, Ross PhanComment